Pathological mechanisms and research progress of multilevel intervention therapy for coronary heart disease

Coronary heart disease (CHD) is a chronic cardiovascular disease with coronary atherosclerosis as the main pathological basis. Its occurrence and progression are not a simple process of lipid deposition, but a systemic pathological process jointly driven by metabolic disorders, chronic low-grade inflammation, and immune imbalance. Recent studies have shown that endothelial dysfunction is a key event in the early occurrence of CHD. Abnormal lipid metabolism, immune cell infiltration, and continuous activation of inflammatory signals together promote plaque formation, maturation, and destabilization. Especially under the regulation of the metabolism-inflammation-immunity network, a positive feedback loop is formed between immune cell metabolic reprogramming, macrophage polarization, inflammasome activation, and oxidative stress response, which accelerates the progression of atherosclerosis and increases the risk of acute coronary events. Traditional therapeutic strategies centered on lipid-lowering, antiplatelet therapy, and revascularization can reduce the incidence of short-term events, but there are still limitations in long-term risk control and fundamental reversal of the disease. From a narrative perspective, this article summarizes the research progress of CHD in pathological mechanisms, metabolism and immune regulation, plaque instability, and risk factors from a systematic perspective and focuses on discussing the potential value of multilevel and systematic intervention strategies in the precise prevention and treatment of CHD, providing a theoretical basis for future translational research and personalized treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-04-13
DOI
https://doi.org/10.3389/fimmu.2026.1816199
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pathological mechanisms and research progress of multilevel intervention therapy for coronary heart disease

Yuanpeng Liao, Zhengdong Wan, Jiawei Guo, Zhongquan Zhou et al.
Frontiers in Immunology
Atherosclerosis and Cardiovascular Diseases
article

Pathological mechanisms and research progress of multilevel intervention therapy for coronary heart disease

Yuanpeng Liao, Zhengdong Wan, Jiawei Guo, Zhongquan Zhou, Yuxin Wei, Zhengyu Tu
article en

Abstract

Coronary heart disease (CHD) is a chronic cardiovascular disease with coronary atherosclerosis as the main pathological basis. Its occurrence and progression are not a simple process of lipid deposition, but a systemic pathological process jointly driven by metabolic disorders, chronic low-grade inflammation, and immune imbalance. Recent studies have shown that endothelial dysfunction is a key event in the early occurrence of CHD. Abnormal lipid metabolism, immune cell infiltration, and continuous activation of inflammatory signals together promote plaque formation, maturation, and destabilization. Especially under the regulation of the metabolism-inflammation-immunity network, a positive feedback loop is formed between immune cell metabolic reprogramming, macrophage polarization, inflammasome activation, and oxidative stress response, which accelerates the progression of atherosclerosis and increases the risk of acute coronary events. Traditional therapeutic strategies centered on lipid-lowering, antiplatelet therapy, and revascularization can reduce the incidence of short-term events, but there are still limitations in long-term risk control and fundamental reversal of the disease. From a narrative perspective, this article summarizes the research progress of CHD in pathological mechanisms, metabolism and immune regulation, plaque instability, and risk factors from a systematic perspective and focuses on discussing the potential value of multilevel and systematic intervention strategies in the precise prevention and treatment of CHD, providing a theoretical basis for future translational research and personalized treatment.

Frontiers in ImmunologyVol. 17
Yangtze University (CN)
Health Commission of Hubei Province, National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 20%
Atherosclerosis and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.